Our Team

Each Partner brings extensive industry knowledge, unrivaled relationships and substantial deal experience, resulting in a team of the industry's most sought after advisors

Jason W. Lee

Jason Lee joined Centerview Partners in 2012 and is a Partner in the San Francisco office. At Centerview, Mr. Lee has advised a broad range of life science companies across strategic advisory assignments and transactions exceeding $175 billion in value.

Mr. Lee’s recent notable healthcare transactions include advising Seagen on its sale to Pfizer for $44 billion, Immunomedics on its sale to Gilead for $21 billion, Array BioPharma on its sale to Pfizer for $11.8 billion, AveXis on its sale to Novartis for $8.7 billion, GW Pharmaceuticals on its sale to Jazz Pharmaceuticals for $7.2 billion, Tesaro on its sale to GSK for $5.1 billion, Forty Seven Therapeutics on its sale to Gilead for $4.9 billion, Dicerna Pharmaceuticals on its sale to Novo Nordisk for $3.3 billion, ArQule on its sale to Merck for $2.7 billion, Ra Pharma on its sale to UCB for $2.5 billion, Synthorx on its sale to Sanofi for $2.5 billion, Peloton Therapeutics on its sale to Merck for up to $2.2 billion, Constellation Pharmaceuticals on its sale to MorphoSys for $1.7 billion, ARMO on its sale to Eli Lilly for $1.6 billion, Imago Biosciences on its sale to Merck for $1.3 billion, Syntimmune on its sale to Alexion for up to $1.2 billion, Eidos Therapeutics on its $1.1 billion sale of the publicly-traded minority shares to BridgeBio, Lengo Therapeutics on its sale to Blueprint for up to $465 million, Pionyr on its option transaction with Gilead.

Other notable transactions include advising Pharmacyclics on its sale to AbbVie for $21 billion, Kite Pharma on its sale to Gilead for $11.9 billion, Onyx on its sale to Amgen for $10.4 billion, InterMune on its sale to Roche for $8.9 billion, Dyax on its sale to Shire for $6.6 billion, Avanir on its sale to Otsuka for $3.5 billion, Relypsa on its sale to Galenica for $1.5 billion, Cadence on its sale to Mallinckrodt for $1.3 billion, MAP Pharmaceuticals on its sale to Allergan for $1 billion, Optimer and Trius on their sale to Cubist for $0.8 billion and $0.8 billion, respectively, Raptor on its sale to Horizon for $0.8 billion, XenoPort on its sale to Arbor for $500 million.

Mr. Lee holds an M.B.A. from Cornell University and a B.S. in Microbiology and Molecular Genetics from University of California, Los Angeles.
Centerview Partners takes a “One Firm” approach to deliver unmatched intellectual capital and integrity to all of our clients. We have industry-leading expertise in:

Centerview is honored to partner with leading charitable organizations in active support of our charities:

  • Arts Connection
  • NY Cares
  • Bottomless Closet
Revlon, Inc.
Announced: Q2 2023
Status: Pending

Exclusive investment banker to the BrandCo Ad-Hoc Group to Revlon on the Company's Plan of Reorganization
View All
New York

Centerview Partners LLC

31 West 52nd Street

22nd Floor

New York, New York 10019

(212) 380-2650 | Tel
(212) 380-2651 | Fax

Centerview Partners UK LLP

100 Pall Mall

3rd Floor

London SW1Y 5NQ

02074099700 | Tel
02074099704 | Fax

Centerview Partners France SCS

16 Avenue Matignon

4th Floor

Paris 75008

0180200620 | Tel
0180200621 | Fax
Palo Alto

Centerview Partners LLC

600 Ramona St.

Suite 300

Palo Alto, California 94301

(650) 822-5800 | Tel
(650) 822-5801 | Fax
San Francisco

Centerview Partners LLC

555 California Street

Suite 4300

San Francisco, California 94104

(415) 400-0900 | Tel
(415) 400-0901 | Fax

Copyright © 2008 - 2023 Centerview Partners Holdings LP. All Rights Reserved. | Privacy and Other Notices

Centerview Partners LLC, member SIPC